跳至主要内容
临床试验/NCT00133809
NCT00133809已完成2 期

Islet Transplantation in Type 1 Diabetes Using the Edmonton Protocol of Steroid Free Immunosuppression

Emory University1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2002年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
8
试验地点
1
主要终点
The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation

研究概览

简要总结

This trial will study the ability of islet transplantation to restore glycemic control and achieve insulin independence in type 1 diabetic subjects with life-threatening hypoglycemia and unawareness, or recurrent hyperglycemia with ketoacidosis.

详细描述

LAY SUMMARY:

More than 1 million North Americans have type 1 diabetes. Each year, approximately 30,000 new cases of type 1 diabetes are diagnosed in the United States. Type 1 diabetes destroys islets, a cluster of cells within the pancreas that produce insulin. Insulin is a hormone with many effects. However, the most important effect of insulin is to control the level of sugar in the blood. People with Type 1 diabetes no longer produce insulin and must take insulin injections to live. Despite steady improvements in the management of this disease, its victims remain at increased risk for stroke, heart attack, kidney failure, amputation, blindness, nerve damage and premature death. The life expectancy of a teenager is reduced by thirty years from the time of onset of the disease. Unfortunately, many type 1 diabetics cannot control their blood sugars in spite of very careful monitoring and the frequent injection of insulin. This group of patients is considered to have labile or "brittle" diabetes. These "brittle" diabetics can often have wide swings in their blood sugar levels that can be life threatening. Hypoglycemia, or low blood sugars, occurs when too much insulin is in the bloodstream. When this occurs, it is vital that patients eat or drink something right away that will increase their blood sugars. Many diabetics lose the ability to recognize when their blood sugars are getting dangerously low. These episodes of hypoglycemia can lead to coma, and possibly death, if not recognized and treated right away. Patients can also experience extreme increases in blood sugars, or hyperglycemia, as a result of emotional or physical stress. Hyperglycemia can result in dehydration, confusion, and a condition called ketoacidosis, which can lead to death. When this happens, insulin must be given as soon as possible.

Islet transplantation can restore the body's ability to make insulin and, in turn, restore normal blood sugar levels.

Since the 1960's, doctors and scientists have attempted to replace this islet function by performing whole organ pancreas transplantation. While the results of pancreas transplantation have improved dramatically in recent years, this approach has largely been limited to patients with kidney disease who have also needed a kidney transplant. This is because of the risks associated with the surgical procedure and the immunosuppressive drugs required to prevent rejection or the destruction of the transplanted pancreas by the body's immune system. Transplantation of a whole pancreas requires a major operation that is done through an incision in the abdomen. The patient must be under general anesthesia, or asleep, for the entire procedure. Recent clinical experience suggests that islet transplantation may be a useful approach to correct diabetes in humans.

Islet transplantation offers a direct approach to the treatment of type 1 diabetes. A large number of experimental studies carried out in many laboratories over the last decade have documented the beneficial effects of islet transplants in experimental animals. These experiments have confirmed both the efficiency and safety of islet transplantation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes mellitus diagnosed > 5 years previously
  • Body mass index less than or equal to 26
  • 18 to 65 years of age
  • Compliance with an optimized diabetic management plan as assessed by an Emory University endocrinologist
  • Checking and recording blood sugars at least 3 times per day
  • Intensive insulin therapy (injecting insulin at least 3 times a day or using an insulin pump)
  • Severe hypoglycemia and/or hyperglycemia. Severe hypoglycemia is defined by: episodes requiring assistance by others and/or hypoglycemic unawareness (the inability to recognize blood glucose < 54 mg/dL). Severe hyperglycemia is defined by: two episodes of ketoacidosis requiring hospitalization within the past year.

排除标准

  • Renal dysfunction
  • Severe co-existing cardiac disease, characterized by any one of these conditions: recent myocardial infarction (within past six months); angiographic evidence of non-correctable coronary artery disease; or evidence of ischemia on a dobutamine stress echocardiogram.
  • Current bacterial or fungal infection
  • Macroproteinuria
  • Baseline hemoglobin < 11.4 gm/dL in women; < 12.9 gm/dL in men.
  • Hyperlipidemia
  • Positive tests for human immunodeficiency virus (HIV), or hepatitis B or C
  • Negative antibody test for varicella zoster virus (subjects may be reconsidered if they receive the vaccination and convert to a positive antibody)
  • History of malignancy (except squamous or basal cell skin carcinoma)
  • Previous/concurrent organ transplantation
  • Presence of HLA panel reactive antibodies > 20%
  • Active peptic ulcer disease
  • Evidence of gallbladder disease including cholecystitis and cholelithiasis
  • Evidence of liver disease including hepatic neoplasm, portal hypertension, or persistently abnormal liver function tests.
  • Persistent coagulopathy or current use of anticoagulants (not including aspirin)
  • Sickle cell anemia
  • Positive pregnancy test, intent for future pregnancy, failure to follow effective contraceptive measures, or presently breastfeeding
  • Active alcohol or substance abuse. This includes smoking (must be abstinent for six months). Active alcohol abuse should be considered using the current National Institute on Alcohol Abuse and Alcoholism (NIAAA) definitions.
  • Psychiatric disorder making the subject not a suitable candidate for transplantation
  • Current use of systemic steroid medications
  • Evidence of insulin resistance (insulin requirement > 1.2 units/kg/day)
  • Inability to provide informed consent
  • Any condition or any circumstance that makes it unsafe to undergo an islet transplant

研究组 & 干预措施

Islet Transplant

Experimental

All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant

干预措施: Transplantation of Human Islets (Drug)

结局指标

主要结局

The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation

时间窗: one year after transplant

Independence from insulin injections is measured by the actual use of insulin by the study participants.

次要结局

  • Number of Subjects With HbA1C ≤ 6.5%(1, 3, 6, 9,12,18,24, 36, 48 and 60 months post-transplantation)
  • The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL(1, 3, 6, 9,12,18, 24, 36, 48 and 60 months post-transplantation)
  • Number of Insulin-independent Subjects Following Islet Transplantation(1, 3, 6, 9,12,18, 24, 36, 48 and 60 months post-transplantation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nicole Turgeon MD

Associate Professor

Emory University

研究点 (1)

Loading locations...

相似试验

Islet Transplantation in Type 1 Diabetics Using the... | 临床试验